Literature DB >> 22248180

Inhibition of nuclear transcription factor-κB and activation of peroxisome proliferator-activated receptors in HepG2 cells by cucurbitane-type triterpene glycosides from Momordica charantia.

Nguyen Xuan Nhiem1, Pham Hai Yen, Nguyen Thi Thanh Ngan, Tran Hong Quang, Phan Van Kiem, Chau Van Minh, Bui Huu Tai, Nguyen Xuan Cuong, Seok Bean Song, Young Ho Kim.   

Abstract

Momordica charantia is used to treat various diseases, including inflammatory conditions. Previous reports indicated that the extract of this plant inhibits activation of nuclear transcription factor-κB (NF-κB) but activates peroxisome proliferator-activated receptor (PPAR). Additionally, cucurbitane-type triterpene glycosides are the main bioactive components of the fruit of M. charantia. Therefore, we investigated the anti-inflammatory activity of 17 cucurbitane-type triterpene glycosides (1-17) isolated from this plant. Their inhibition of NF-κB and activation of PPAR activities in HepG2 cells were measured using luciferase reporter and PPAR subtype transactivation assays. Compounds 6 and 8 were found to inhibit NF-κB activation stimulated by tumor necrosis factor-α (TNFα) in a dose-dependent manner. With 50% inhibition concentration (IC(50)) values of 0.4 μM, compounds 6 and 8 were more potent inhibitors than the positive control, sulfasalazine (IC(50)=0.9 μM). Compounds 4, 6, and 8 also inhibited TNFα-induced expressions of inducible nitric oxide synthase and cyclooxygenase-2 mRNA. However, only compound 13 significantly increased PPARγ transactivation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22248180      PMCID: PMC3308713          DOI: 10.1089/jmf.2011.1766

Source DB:  PubMed          Journal:  J Med Food        ISSN: 1096-620X            Impact factor:   2.786


  30 in total

Review 1.  NF-kappaB: a key role in inflammatory diseases.

Authors:  P P Tak; G S Firestein
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 2.  Series introduction: the transcription factor NF-kappaB and human disease.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 3.  PPARs and the complex journey to obesity.

Authors:  Ronald M Evans; Grant D Barish; Yong-Xu Wang
Journal:  Nat Med       Date:  2004-04       Impact factor: 53.440

4.  Differential effects of foods traditionally regarded as 'heating' and 'cooling' on prostaglandin E(2) production by a macrophage cell line.

Authors:  Ching Jang Huang; Mei-Chiao Wu
Journal:  J Biomed Sci       Date:  2002 Nov-Dec       Impact factor: 8.410

Review 5.  Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation.

Authors:  Y J Surh; K S Chun; H H Cha; S S Han; Y S Keum; K K Park; S S Lee
Journal:  Mutat Res       Date:  2001-09-01       Impact factor: 2.433

6.  PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.

Authors:  C Jiang; A T Ting; B Seed
Journal:  Nature       Date:  1998-01-01       Impact factor: 49.962

7.  Induction of anti-inflammatory responses by dietary Momordica charantia L. (bitter gourd).

Authors:  Mariko Manabe; Ryo Takenaka; Teruko Nakasa; Osamu Okinaka
Journal:  Biosci Biotechnol Biochem       Date:  2003-12       Impact factor: 2.043

8.  Bitter gourd (Momordica charantia) extract activates peroxisome proliferator-activated receptors and upregulates the expression of the acyl CoA oxidase gene in H4IIEC3 hepatoma cells.

Authors:  Che-Yi Chao; Ching-jang Huang
Journal:  J Biomed Sci       Date:  2003 Nov-Dec       Impact factor: 8.410

9.  Inhibition of nitric oxide generation by 23,24-dihydrocucurbitacin D in mouse peritoneal macrophages.

Authors:  Chang Seok Park; Hyun Lim; Kee Jung Han; Sun Heum Baek; Hyung Ok Sohn; Dong Wook Lee; Yang-Gyun Kim; Hye-Young Yun; Kwang Jin Baek; Nyoun Soo Kwon
Journal:  J Pharmacol Exp Ther       Date:  2004-01-29       Impact factor: 4.030

Review 10.  Pharmacological actions and potential uses of Momordica charantia: a review.

Authors:  J K Grover; S P Yadav
Journal:  J Ethnopharmacol       Date:  2004-07       Impact factor: 4.360

View more
  7 in total

1.  Molecular mechanisms of cholangiocarcinoma cell inhibition by medicinal plants.

Authors:  Surang Leelawat; Kawin Leelawat
Journal:  Oncol Lett       Date:  2016-12-12       Impact factor: 2.967

Review 2.  Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.

Authors:  Komal Raina; Dileep Kumar; Rajesh Agarwal
Journal:  Semin Cancer Biol       Date:  2016-07-21       Impact factor: 15.707

3.  A triterpenoid from wild bitter gourd inhibits breast cancer cells.

Authors:  Li-Yuan Bai; Chang-Fang Chiu; Po-Chen Chu; Wei-Yu Lin; Shih-Jiuan Chiu; Jing-Ru Weng
Journal:  Sci Rep       Date:  2016-03-01       Impact factor: 4.379

Review 4.  The Effect of Momordica charantia in the Treatment of Diabetes Mellitus: A Review.

Authors:  Zhuo Liu; Jing Gong; Wenya Huang; Fuer Lu; Hui Dong
Journal:  Evid Based Complement Alternat Med       Date:  2021-01-16       Impact factor: 2.629

5.  Natural Compound 3β,7β,25-trihydroxycucurbita-5,23(E)-dien-19-al from Momordica charantia Acts as PPARγ Ligand.

Authors:  Nur Adelina Ahmad Noruddin; Mohamad Faiz Hamzah; Zulfadli Rosman; Nurul Hanim Salin; Alexander Chong Shu-Chien; Tengku Sifzizul Tengku Muhammad
Journal:  Molecules       Date:  2021-05-03       Impact factor: 4.411

Review 6.  Overview of Botanical Status in EU, USA, and Thailand.

Authors:  Weena Jiratchariyakul; Gail B Mahady
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-21       Impact factor: 2.629

Review 7.  Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review.

Authors:  Limei Wang; Birgit Waltenberger; Eva-Maria Pferschy-Wenzig; Martina Blunder; Xin Liu; Clemens Malainer; Tina Blazevic; Stefan Schwaiger; Judith M Rollinger; Elke H Heiss; Daniela Schuster; Brigitte Kopp; Rudolf Bauer; Hermann Stuppner; Verena M Dirsch; Atanas G Atanasov
Journal:  Biochem Pharmacol       Date:  2014-07-30       Impact factor: 5.858

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.